FIELD: chemistry.
SUBSTANCE: invention relates to a biaryl derivative represented by chemical formula 1, or a pharmaceutically acceptable salt or isomer thereof, where A and B independently denote C6-C10aryl or 5–12-member heteroaryl containing 1–3 heteroatoms selected from N, O and S; D and E can independently be absent or independently denote C, CH, CH2, N, NH, O or S; R1 and R2 can independently be absent or independently denote hydrogen, C1-C6alkyl, C3-C6cycloalkyl, 3-6-member heterocycloalkyl, C1-C6alkyl-C3-C6cycloalkyl, C3-C6cycloalkyl-C1-C6alkyl, halogen-C1-C6alkyl, C1-C6alkoxy, C1-C6alkoxy-C1-C6alkyl, C1-C6alkoxy-phenyl, C3-C6cycloalkoxy, C3-C6cycloalkyl-C1-C6alkoxy, phenyl, C1-C6alkyl-phenyl, phenyl-C1-C6alkyl, halogen-phenyl, pyridinyl, C1-C6alkyl-pyridinyl or halogen-C1-C6alkyl-phenyl, where heterocycloalkyl contains at least one heteroatom selected from O and S; R1 and R2 can be bonded to each other or to D and / or E to form 5–15-member heterocycle containing 1–3 heteroatoms selected from N and O, condensed with A; wherein said heterocycle is optionally substituted with C1-C6alkyl, halogen, C1-C6alkoxycarbonyl, C3-C6cycloalkyl-C1-C6alkyl, halogen-phenyl or C1-C6alkyl-phenyl; and when D and E denote C, CH, S or N, R1 and R2 can denote two or three C1-C6alkyl, oxo, C3-C6cycloalkyl or C1-C6alkoxy, which may be identical or different; R3 and R4 independently denote hydrogen, halogen, C1-C6alkyl, C3-C6cycloalkyl, C1-C6alkoxy, nitrile, oxo, C1-C6alkylamine or C3-C6cycloalkylamine; m and n independently denote integer from 0 to 2; G is -(CR5R6)p-J-(CR5R6)q, wherein J denotes CH2, O, N, NH, S or a double bond; R5 and R6 independently denote hydrogen, halogen or C1-C6alkyl, or can be connected to each other to form C3-C6cycloalkyl, and when J is N, each of R5 and R6 in two (CR5R6) can be bonded to form 5-6-member heteroaryl or 5-6-member heterocycloalkyl containing 1 or 2 N atoms, or can be substituted with C1-C6alkyl; and p and q independently denote integer from 0 to 4; and R7 denotes a -COOH group or isoster thereof, selected from a group consisting of isoxazolol, pyrazolol, isothiazolol, thiadiazolidinone, thiazolidinedione, pyridinol, dioxothiadiazolidinone, tetrazole, triazole, sulphonamide, acetamide, nitrile, hydroxyacetamidine, oxadiazolone and oxadiazolthione. Invention also refers to a pharmaceutical composition possessing the GPR120 agonist properties, based on said compound. [Formula 1]
.
EFFECT: technical result is obtaining a novel compound and a pharmaceutical composition based thereon, which can be used in medicine for treating inflammation or metabolic diseases, such as diabetes, complications of diabetes, obesity, non-alcoholic obesity of liver, obesity of liver and osteoporosis.
6 cl, 1 tbl, 622 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BIARYL DERIVATIVES AS AGONISTS GPR120 | 2014 |
|
RU2641003C2 |
| 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | 2012 |
|
RU2612958C2 |
| NEW AMINOARYL DERIVATIVE SUITABLE AS A DIACYLGLYCEROLACYL TRANSFERASE 2 INHIBITOR AND ITS APPLICATION | 2020 |
|
RU2799819C1 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2015 |
|
RU2734390C2 |
| TRICYCLIC BENZOXABORAL COMPOUND, METHOD FOR ITS PRODUCTION AND ITS APPLICATION | 2014 |
|
RU2639153C2 |
| NOVEL DERIVATIVE OF PURINYLPYRIDINYLAMINO-2,4-DIFLUOROPHENYLSULPHONAMIDE, ITS PHARMACEUTICALLY ACCEPTABLE SALT, METHOD OF ITS OBTAINING AND PHARMACEUTICAL COMPOSITION, WHICH HAS INHIBITION ACTIVITY WITH RESPECT TO RAF-KINASE, CONTAINING CLAIMED COMPOUND AS ACTIVE INGREDIENT | 2011 |
|
RU2550038C2 |
| MKK4 PROTEIN KINASE INHIBITORS FOR STIMULATION OF LIVER REGENERATION OR REDUCTION OR PREVENTION OF HEPATOCYTE DEATH | 2019 |
|
RU2788000C2 |
| TETRAHYDROPYRIDINE DERIVATIVES AND USE THEREOF AS ANTIBACTERIAL AGENTS | 2017 |
|
RU2722594C1 |
| NEW BIARYL DERIVATIVE USED AS INHIBITOR OF DIACYLGLYCEROL ACYLTRANSFERASE 2 AND ITS USE | 2021 |
|
RU2808433C1 |
| HETEROCYCLIC DERIVATIVES AND USE THEREOF | 2014 |
|
RU2681849C2 |
